UNSPSC 51421801: Rofleponide

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H34F2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9IQ7GVL3E, chemically known as 6 alpha, 9-difluoro-11 beta, 16 alpha, 17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (r)-16,17-acetal with butyraldehyde. but generally known as rofleponide, which bears US NIH Compound Identifier 3055174. European Medicines Agency schedules Rofleponide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10357MIG.

UNSPSC 51421801 Rofleponide is a Commodity code that maps poorly to actual state and local procurement activity in the recent opportunities record. The code nominally covers a specific pharmaceutical compound, but the two recent solicitations tagged under it—one for naloxone and drug deactivation systems, the other for direct-to-manufacturer prescription program capabilities—do not address rofleponide. Seminole County, Florida's IFB for naloxone procurement and the Texas Health and Human Services Commission's RFI for therapeutic pharmacy initiative vendor capabilities represent health department and state agency health program buying, but neither targets the specific drug product the code nominally describes. The mismatch suggests either miscoding in the source data or that rofleponide purchasing does not currently generate visible state and local RFP, RFQ, IFB, or ITB activity at the jurisdictional level.

The geographic spread evident in the two opportunities spans Florida and Texas, but neither solicitation is material to rofleponide-specific procurement. Seminole County's naloxone bid (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida. The Texas HHS Commission's RFI (HHS0017013, response due April 3, 2026) focused on vendor capability to support direct-to-manufacturer prescription programs for state employee and retiree health plans, not on specific pharmaceutical products. State and local procurement analysts should treat this code as inactive for rofleponide supply and verify the correct UNSPSC classification if rofleponide sourcing is a business target.